Abiopharma

New Form S-3/A - Tharimmune, Inc. Filed: 2025-09-03 AccNo: 0001641172-25-026303 Size: 152 KB

New Form 8-K - STANDARD BIOTOOLS INC. Filed: 2025-09-03 AccNo: 0000950170-25-112662 Size: 194 KB Item 2.05: Cost Associated with Exit or Disposal Activities

New Form DEFR14A - BioSig Technologies, Inc. Filed: 2025-09-03 AccNo: 0001641172-25-026300 Size: 29 KB

New Form EFFECT - ACCURAY INC Filed: 2025-09-02 AccNo: 9999999995-25-002800 Size: 1 KB

New Form EFFECT - Galmed Pharmaceuticals Ltd. Filed: 2025-09-02 AccNo: 9999999995-25-002804 Size: 1 KB

New Form EFFECT - BRIGHT MINDS BIOSCIENCES INC. Filed: 2025-09-02 AccNo: 9999999995-25-002807 Size: 1 KB

New Form EFFECT - Galmed Pharmaceuticals Ltd. Filed: 2025-09-02 AccNo: 9999999995-25-002797 Size: 1 KB

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best-In-Class PRMT5 Inhibitor for MTAP-Deletion Solid Tumors

Mahadevia Ankit 🔴 sold 6.6K shares of Spero Therapeutics, Inc. (SPRO) at $1.97 Transaction Date: Aug 28, 2025 | Filing ID: 112661

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Aclarion Appoints Greg Gould as Chief Financial Officer

Employee Stock Option/ Share Scheme: NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) - OTHER ISSUE OF SECURITIES

Hyphens Notification - Evolve Capitals Equity Research - 1H25: Near Term Performance Likely to Remain Subdued Before Modest Recovery

Evolve Capital’s Equity Research – Near Term Performance Likely to Remain Subdued Before Modest Recovery

General Announcement: CHANGES IN SUBSTANTIAL SHAREHOLDERS INTEREST PURSUANT TO SECTION 138 OF THE COMPANIES ACT 2016